BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38306380)

  • 1. MALT Lymphoma in Histologic Transformation: FDG-Avid but Pentixafor-Negative.
    Tang R; Chen X; Liu M; Shu Q; Cai L
    Clin Nucl Med; 2024 Mar; 49(3):276-277. PubMed ID: 38306380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report.
    Ren Y; Huang L; Han Y; Cui Z; Li J; Dong C; Liu J
    Medicine (Baltimore); 2019 Feb; 98(5):e14270. PubMed ID: 30702589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET/CT Findings of MALT Lymphoma of Ureter.
    He L; Deng Y; Deng Y; Xie H; Zhang W
    Clin Nucl Med; 2022 Sep; 47(9):828-829. PubMed ID: 35930711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating breast mucosa-associated lymphoid tissue lymphoma: A case series.
    Albano D; Bosio G; Orlando E; Bertagna F
    Hematol Oncol; 2017 Dec; 35(4):884-889. PubMed ID: 28004400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary mucosa-associated lymphoid tissue lymphoma:
    Albano D; Borghesi A; Bosio G; Bertoli M; Maroldi R; Giubbini R; Bertagna F
    Br J Radiol; 2017 Nov; 90(1079):20170311. PubMed ID: 28830222
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Albano D; Durmo R; Treglia G; Giubbini R; Bertagna F
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):137-146. PubMed ID: 32029397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement.
    Park SH; Lee JJ; Kim HO; Lee DY; Suh C; Jung HY; Choi KD; Kim DH; Huh J; Ryu JS
    Leuk Lymphoma; 2015; 56(12):3288-94. PubMed ID: 25804932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type.
    Hoffmann M; Kletter K; Diemling M; Becherer A; Pfeffel F; Petkov V; Chott A; Raderer M
    Ann Oncol; 1999 Oct; 10(10):1185-9. PubMed ID: 10586335
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
    J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography integrated with computed tomography for accurate staging and surveillance in the case of mucosa-associated lymphoid tissue.
    Zhang S; Rossetti-Chung A; Sood S; Terezakis S
    J Radiol Case Rep; 2021 Mar; 15(3):19-28. PubMed ID: 34267867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG Versus 68Ga-FAPI PET/CT in Visualizing Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue.
    Pang Y; Zhao L; Shang Q; Meng T; Chen H
    Clin Nucl Med; 2022 Apr; 47(4):375-377. PubMed ID: 34661557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis.
    Treglia G; Zucca E; Sadeghi R; Cavalli F; Giovanella L; Ceriani L
    Hematol Oncol; 2015 Sep; 33(3):113-24. PubMed ID: 25047160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burkitt Lymphoma/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET/CT.
    Chen Z; Xue Q; Huang C; Yao S; Miao W
    Clin Nucl Med; 2022 Jan; 47(1):98-100. PubMed ID: 34115701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication.
    Mayerhoefer ME; Raderer M; Lamm W; Weber M; Kiesewetter B; Rohrbeck J; Simonitsch-Klupp I; Hacker M; Leisser A; Nics L; Schmitl S; Wester HJ; Haug A
    Blood; 2022 Jan; 139(2):240-244. PubMed ID: 34525196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation.
    Park YJ; Hyun SH; Moon SH; Lee KH; Min BH; Lee JH; Kim WS; Kim SJ; Choi JY
    Sci Rep; 2021 Apr; 11(1):9243. PubMed ID: 33927319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
    Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in primary hepatic mucosa-associated lymphoid tissue lymphoma: A case report and review of the literature.
    Bao C; Wei J; Zhao X; Lin L; Chen D; Liu K; Qian W; Anas JM; Zhao K
    Medicine (Baltimore); 2018 Mar; 97(10):e9877. PubMed ID: 29517697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT and primary hepatic MALT: a case series.
    Albano D; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2016 Oct; 41(10):1956-9. PubMed ID: 27259334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
    Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
    Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.